ECI Pharmaceuticals listed conjugated estrogens instead of esterified estrogens for two drugs, FDA says.
What happened
FDA reviewed ECI Pharmaceuticals’ electronic drug listing information for two esterified estrogens and methyltestosterone products (NDC 51293-639 and 51293-640). FDA found the listing file named conjugated estrogens as an active ingredient while the labeling named esterified estrogens, and it noted earlier deficiency and removal notices dated October 26 and December 10, 2021.
What FDA found
The listing must include the name and quantity of each active ingredient.
FD&C Act section 510(j)(1)(C), 21 U.S.C. 360The active ingredient in the electronic listing did not match the active ingredient on the labeling.
FD&C Act section 510(j); 21 CFR 207Failure to properly list the drug makes it misbranded.
FD&C Act section 502(o), 21 U.S.C. 352(o); section 301(a), 21 U.S.C. 331(a)Failure to meet the listing obligations is a prohibited act.
FD&C Act section 301(p), 21 U.S.C. 331(p)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt of the letter with the specific steps taken, an explanation of steps to prevent recurrence, and related documentation; if corrective actions cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- drug listing and regulatory affairs staff
- companies with estrogen/methyltestosterone drug listings
- pharmacies and e-prescribing systems using NDC directory data
This is a summary. Read the original letter on fda.gov.